Share Name Share Symbol Market Type Share ISIN Share Description
Collagen Sol LSE:COS London Ordinary Share GB00B94T6Y14 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 6.25p 6.00p 6.50p 6.25p 6.25p 6.25p 40,000.00 08:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 3.1 -0.9 -0.6 - 11.23

Collagen Sol (COS) Latest News (1)

More Collagen Sol News
Collagen Sol Takeover Rumours

Collagen Sol (COS) Share Charts

1 Year Collagen Sol Chart

1 Year Collagen Sol Chart

1 Month Collagen Sol Chart

1 Month Collagen Sol Chart

Intraday Collagen Sol Chart

Intraday Collagen Sol Chart

Collagen Sol (COS) Discussions and Chat

Collagen Sol (COS) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
02/12/2016 08:19:526.0040,0002,400.00O
View all Collagen Sol trades in real-time

Collagen Sol (COS) Top Chat Posts

DateSubject
02/12/2016
08:20
Collagen Sol Daily Update: Collagen Sol is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker COS. The last closing price for Collagen Sol was 6.25p.
Collagen Sol has a 4 week average price of 6.31p and a 12 week average price of 7.21p.
The 1 year high share price is 10.13p while the 1 year low share price is currently 5.25p.
There are currently 179,621,290 shares in issue and the average daily traded volume is 21,360 shares. The market capitalisation of Collagen Sol is £11,226,330.63.
29/2/2016
10:06
interstellar: JJ- are you trying to ramp this stock. You know it's really very disappointing to get an alert from ADVFN that a new post has been made only to find unsubstantiated twaddle. "Pipeline there and being traversed "- well that is yet to be demonstrated as the company freely admits in its own recent comments- otherwise they would not suffer from delays to revenue flows with its consequent impact on the share value; " its a case of how fast and at what time we get the next news.." -there is no guarantee at this stage or any optimism expressed by the management, that they have successfully filled the sales pipeline with potential contracts; " but could well be probably biggest news ever for the company in my opinion." Admirable enthusiasm but wildly optimistic at this stage. The fact that the share price is a mere 50% of where it was not so long ago testifies to the risks here. The company has a huge senior management team with all its various subsidiaries- very expensive- and , so far, they have shown little sign of delivering what they promised. Don't bet the farm on this one- in fact prepare to lose your shirt! All in my humble opinion
26/1/2016
19:45
jacobjohn7: He's had his winners I believe also, anyway him buying doesnt make the company. Do your research every one sat waiting for big deals to materialise. The acquisitions of COS have been very astute imo. I agree though the sales targets can slip timescale wise not a biggie, as long as these things gain traction and sales targets are hit, and the pipeline lives up to anywhere near the great promise it upholds. I think the 100m market cap is a good thing to aim for as a medical business, but that in itself puts pressure on the share price.. as it is ambitious, but it is an ambitious company with a good global reach and offering.
26/1/2016
18:53
interstellar: Well Jaco, BEWARE! it's a ploy David Evans has used before. He and his fellow directors bought a shed load of EKF shares (at around 25pence per) in order to show support for EKF's underlying business. Even at the time fully aware of the poison pill some of that company's acquisitions had proven to be. Today EKF's share price is 8p- 2/3rds of the value lost. IF you dont believe me check out EKF's history over the last year or so. So don't make any judgements about director's purchases- history here has shown it to not necessarily be a wise move or good guide. What will make a difference to COS price is hitting sales targets, getting more contracts in the pipeline so mealy mouthed excuses of 'timing' issues are a thing of the past and they get their fingers out and DELIVER what they promise.
20/11/2015
11:24
jacobjohn7: Collagen Solutions buys knee implant for ‘bargain’ PERRY GOURLEY Tuesday 15 September 2015 Life sciences firm Collagen Solutions has struck a deal to buy a product used to repair minor damage to knee joints. The acquisition of the assets and intellectual property (IP) for ChondroMimetic is the last in a string of announcements by the Glasgow-based firm as it looks to grow to a £100 million business in the next five years. ChondroMimetic is a collagen-based implant for the treatment of small cartilage and underlying bone defects. The market it is aimed at is estimated to be worth more than $500m (£325m). Collagen Solutions chief executive Stewart White said the deal to buy the product from its owners, Cambridge University spin-out Orthomimetics and Cambridge Enterprise, was an important next step for the company as it was the first acquisition of a medical device. White, pictured, said: “Having established Collagen Solutions as the go to company for providing novel medical grade collagens, we were in a position to look at acquiring products that are collagen related and would give us the opportunity to not only provide part of the product, but to add value. “ChondroMimetic is an ideal first medical device acquisition as it brings us both an established product as well as access to a portfolio of additional IP we can exploit in the future.” The acquisition is being funded through the issue of 869,900 shares – about £100,000 at the current share price – with half of the consideration being paid now and the rest over the next two years. Royalties will also be payable to the vendors on future sales. Analyst Mike Mitchell of house broker Panmure Gordon estimates that the total value of the deal will be “low hundreds of thousands”. He viewed the acquisition as “something of a bargain” given the background to the product. “ChrondroMimetic was Orthomimetics’ key product and investors familiar with this space will recall Belgium-based TiGenix acquiring Orthomimetics in 2009 in a deal valuing the company at €16m (£11.75m),” he pointed out. Mitchell said that any product launch by Collagen Solutions based on the acquisition was some way off as a number of regulatory and manufacturing challenges would need to be navigated. “But we consider the market opportunity to be attractive, playing well with respect to population demographics and increasing demand for effective early interventions which avoid or reduce the need for more expensive treatments in later life.” Ian Harris, director of Orthomimetics, said Collagen Solutions “had the resources and knowledge-base to see ChondroMimetic build on its early promise”. Earlier this month Collagen Solutions said one of its long-term clients had gained US approval for a new device that makes collagen products easier to use. In September it was chosen to take part in a €4m European research project aimed at developing new treatments for Parkinson’s disease. Read more: http://www.scotsman.com/business/companies/collagen-solutions-buys-knee-implant-for-bargain-1-3886455#ixzz3s1uk585H Follow us: @TheScotsman on Twitter | TheScotsmanNewspaper on Facebook
Collagen Sol share price data is direct from the London Stock Exchange
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:41 V: D:20161203 04:34:47